The Union Ministry of Health and Family Welfare has introduced key amendments to the New Drugs and Clinical Trials (NDCT) Rules, 2019, with the aim of streamlining regulatory processes and reducing approval timelines. These changes are designed to enhance the clinical research and pharmaceutical development landscape by simplifying procedures and promoting ease of doing business. The amendments will not only benefit stakeholders but also ensure public health and safety.
The revised rules will lead to quicker initiation of Bioavailability/Bioequivalence (BA/BE) studies, testing, and drug examination for research purposes. By minimizing delays in the drug development and approval process, the amendments are expected to save a minimum of 90 days in the drug development life cycle. Additionally, the statutory processing timeline for certain categories has been reduced from 90 days to 45 days, as per the Ministry.
The amendments eliminate the requirement for pharmaceutical companies to obtain a test license from the Central Drugs Standard Control Organization (CDSCO) for non-commercial drug manufacture. Instead, a prior-intimation mechanism has been introduced, except for a limited category of high-risk drugs. This change is anticipated to significantly reduce the regulatory burden on the industry and benefit a wide range of stakeholders.
The reforms also do away with the need for prior permission for specific low-risk BA/BE studies, allowing these studies to commence based on a simple online intimation to CDSCO. This streamlined process is expected to expedite the initiation of studies, particularly benefiting the generic pharmaceutical industry. To facilitate the implementation of these changes, dedicated online modules will be accessible on the National Single Window System (NSWS) and the SUGAM portal, ensuring a transparent and convenient process for industry stakeholders. Moreover, these reforms will enhance the efficiency and effectiveness of regulatory oversight by enabling the CDSCO to optimize its existing manpower.
